Evidence-based public health. Prevention and health promotion in the context of science, values and (vested) interests;Evidence-based public health. Prävention und gesundheitsförderung im kontext von wissenschaft, werten und interessen

Medizinische Klinik

Volumn 103, Issue 6, 2008, Pages 406-412

  Gerhardus, Ansgar ^a   Breckenkamp, Jürgen ^b   Razum, Oliver ^a  

^a BIELEFELD UNIVERSITY   (Germany)

^b NONE

Author keywords

Evidence based medicine; Evidence based public health; Public health

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CLINICAL DECISION MAKING; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HUMAN; MEDICAL ETHICS; PAPILLOMA; POPULATION DYNAMICS; PUBLIC HEALTH SERVICE; SOCIAL CLASS; WART VIRUS;

DECISION MAKING, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; FORECASTING; GERMANY; HEALTH PROMOTION; HUMANS; INTERDISCIPLINARY COMMUNICATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVENTIVE HEALTH SERVICES; PUBLIC HEALTH;

HUMAN PAPILLOMAVIRUS;

EID: 45749104450     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1060-9     Document Type: Article

References (22)

1. Winslow CEA. The unfilled field of public health. Mod Med 1920;2:183-91 (zitiert nach: Schneider M-J. Introduction to public health. Sudbury: Jones & Bartlett, 1999).
2. Institute of Medicine. The future of public health. Committee for the Study of the Future of Public Health. Washington: National Academy Press, 1988.
3. Muir Gray JM. Evidence-based public health - what level of competence is required? J Public Health Med 1997;19:65-8.
4. Oxford Centre for Evidence Based Medicine. Oxford Centre for Evidence-based medicine levels of evidence. Oxford: Oxford Centre for Evidence Based Medicine, 2001 (http://www.cebm.net/index.aspx?o=1025, abgerufen am 31. 10. 2007).
5. Guyatt G, Vist G, Falck-Ytter Y, et al., for the the GRADE Working Group. An emerging consensus on grading recommendations [Editorial]? ACP J Club 2006;144:A08-9 (http://www.gradeworkingroup.org/publications/ Guyatt_GRADE_ACPJC2006.pdf, abgerufen am 22. 9. 2007).
6. Kunz R, Lelgemann M, Guyatt G, et al. Von der Evidenz zur Empfehlung. In: Kunz R, Ollenschläger G, Raspe H, et al., Hrsg. Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis, 2. Aufl. Köln: Deutscher Ärzteverlag, 2007:231-49.
7. Underhill K, Montgomery P, Operario D. Sexual abstinence only programmes to prevent HIV infection in high income countries: systematic review. BMJ 2007:doi:10.1136/bmj.39245.446586.BE.
8. West SL, O'Neal KK. Project D.A.R.E. Outcome effectiveness revisited. Am J Public Health 2004;94:1027-9.
9. Waters E, Doyle J. Proposed Cochrane Public Health Review Group. First draft. The Cochrane Collaboration, 2007 (http://ph.cochrane.org/Files/ Scope_PHRG_%20August_29_2007.pdf, abgerufen am 19. 10. 2007).
10. Rychetnik L, Hawe P, Waters E, et al. A glossary for evidence based public health. J Epidemiol Community Health 2004;58:538-45.
11. Des Jarlais DC, Lyles C, Crepaz N, TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004;94:361-6.
12. Vandenbroucke JP, von Elm E, Altman DG, et al., for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;16:e297.
13. Rychetnik L, Frommer M, Hawe P, et al. Criteria for evaluating evidence on public health interventions. J Epidemiol Community Health 2002;56:119-27.
14. Gerhardus A, Stich AK. Sozio-kulturelle Aspekte in Health Technology Assessments (HTA). Z Evid Fortbild Qual Gesundh Wes 2008;102:77-83.
15. Greiner W. Die Rolle der Pharmaökonomie zur Ressourcenallokation im Gesundheitswesen - Überblick und Implikationen für Deutschland. Gesundh Ökon Qual Manag 2007;12:51-6.
16. Perleth M, Busse R, Gerhardus A, et al., Hrsg. Health Technology Assessment. Konzepte, Methoden, Praxis für Wissenschaft und Entscheidungsfindung. Berlin: Medizinisch Wissenschaftlicher Verlag, 2008.
17. Harper DM, Franco EL, Wheeler C, et al., GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
19. Udesky L. Push to mandate HPV vaccine triggers backlash in USA. Lancet 2007;369:979-80.
20. Thiry N, Lambert M-L, Cleemput I, et al. HPV vaccination for the prevention of cervical cancer in Belgium: health technology assessment. Brussels: Belgian Health Care Knowledge Centre (KCE), 2007.
21. Rosenbrock R. Die HPV-Impfung - ein Durchbruch in der Krebsprävention? Dr. med. Mabuse 2007;167:20-2.
22. Rieser S. Ständige Impfkommission: unter Anwendungsbeobachtung. Dtsch Ärztebl 2007;104:A3361.